Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
23.29
-0.13 (-0.56%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Arcutis Biotherapeutics Revenue
In the year 2025, Arcutis Biotherapeutics had annual revenue of $376.07M with 91.34% growth. Arcutis Biotherapeutics had revenue of $129.50M in the quarter ending December 31, 2025, with 81.48% growth.
Revenue (ttm)
$376.07M
Revenue Growth
+91.34%
P/S Ratio
7.75
Revenue / Employee
$1,062,350
Employees
354
Market Cap
2.91B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcus Biosciences | 247.00M |
| Soleno Therapeutics | 190.41M |
| Beam Therapeutics | 139.74M |
| Nektar Therapeutics | 55.23M |
| Alumis | 24.05M |
| Immunome | 6.94M |
ARQT News
- 1 day ago - Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - GlobeNewsWire
- 6 days ago - Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - GlobeNewsWire
- 13 days ago - Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - GlobeNewsWire
- 14 days ago - Arcutis Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 4 weeks ago - Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 weeks ago - Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology - GlobeNewsWire